Literature DB >> 26248365

Fluconazole and Voriconazole Resistance in Candida parapsilosis Is Conferred by Gain-of-Function Mutations in MRR1 Transcription Factor Gene.

Joana Branco1, Ana P Silva2, Raquel M Silva3, Ana Silva-Dias2, Cidália Pina-Vaz2, Geraldine Butler4, Acácio G Rodrigues2, Isabel M Miranda5.   

Abstract

Candida parapsilosis is the second most prevalent fungal agent causing bloodstream infections. Nevertheless, there is little information about the molecular mechanisms underlying azole resistance in this species. Mutations (G1747A, A2619C, and A3191C) in the MRR1 transcription factor gene were identified in fluconazole- and voriconazole-resistant strains. Independent expression of MRR1 genes harboring these mutations showed that G1747A (G583R) and A2619C (K873N) are gain-of-function mutations responsible for azole resistance, the first described in C. parapsilosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26248365      PMCID： PMC4576118          DOI： 10.1128/AAC.00842-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Transcriptional profiling of azole-resistant Candida parapsilosis strains.

Authors:  A P Silva; I M Miranda; A Guida; J Synnott; R Rocha; R Silva; A Amorim; C Pina-Vaz; G Butler; A G Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

3.  A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans.

Authors:  Alix Coste; Vincent Turner; Françoise Ischer; Joachim Morschhäuser; Anja Forche; Anna Selmecki; Judith Berman; Jacques Bille; Dominique Sanglard
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

4.  Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes.

Authors:  Sarah MacPherson; Bassel Akache; Sandra Weber; Xavier De Deken; Martine Raymond; Bernard Turcotte
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.

Authors:  Ana P Silva; Isabel M Miranda; Carmen Lisboa; Cidália Pina-Vaz; Acácio G Rodrigues
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

6.  Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.

Authors:  Ana Teresa Pinto e Silva; Sofia Costa-de-Oliveira; Ana Silva-Dias; Cidália Pina-Vaz; Acácio Gonçalves Rodrigues
Journal:  FEMS Yeast Res       Date:  2009-04-06       Impact factor: 2.796

7.  Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains.

Authors:  Nico Dunkel; Julia Blass; P David Rogers; Joachim Morschhäuser
Journal:  Mol Microbiol       Date:  2008-05-27       Impact factor: 3.501

8.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

9.  A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate.

Authors:  Nico Dunkel; Teresa T Liu; Katherine S Barker; Ramin Homayouni; Joachim Morschhäuser; P David Rogers
Journal:  Eukaryot Cell       Date:  2008-05-16

10.  Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation.

Authors:  Chen Ding; Geraldine Butler
Journal:  Eukaryot Cell       Date:  2007-06-22
View more
  15 in total

1.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast.

Authors:  Cigdem Balkan; Ilkcan Ercan; Esin Isik; Esra Sahin Akdeniz; Orhan Balcioglu; Marie Kodedová; Olga Zimmermannová; Muhammed Dundar; Hana Sychrová; Ahmet Koc
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  In Vitro Antifungal Susceptibility of Neoscytalidium dimidiatum Clinical Isolates from Malaysia.

Authors:  Jasper Elvin James; Jacinta Santhanam; Mei Chen Lee; Choon Xian Wong; Parameswari Sabaratnam; Hamidah Yusoff; Mohd Nizam Tzar; Mohd Fuat Abdul Razak
Journal:  Mycopathologia       Date:  2016-11-04       Impact factor: 2.574

4.  Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains.

Authors:  Christina Popp; Irene A I Hampe; Tobias Hertlein; Knut Ohlsen; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.

Authors:  Laura A Doorley; Jeffrey M Rybak; Elizabeth L Berkow; Qing Zhang; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2022-06-14       Impact factor: 5.938

6.  In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.

Authors:  YanChun Zhu; Shannon Kilburn; Mili Kapoor; Sudha Chaturvedi; Karen Joy Shaw; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Suleyha Hilmioğlu-Polat; Wenjie Fang; Melike Yaşar; Furkan Polat; Dilek Yeşim Metin; Petra Rigole; Tom Coenye; Macit Ilkit; Weihua Pan; Wanqing Liao; Ferry Hagen; Markus Kostrzewa; David S Perlin; Cornelia Lass-Flörl; Teun Boekhout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 8.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Authors:  Sarah G Whaley; Elizabeth L Berkow; Jeffrey M Rybak; Andrew T Nishimoto; Katherine S Barker; P David Rogers
Journal:  Front Microbiol       Date:  2017-01-12       Impact factor: 5.640

9.  Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens.

Authors:  Sourour Neji; Ines Hadrich; Houaida Trabelsi; Salma Abbes; Fatma Cheikhrouhou; Hayet Sellami; Fattouma Makni; Ali Ayadi
Journal:  J Biomed Sci       Date:  2017-09-04       Impact factor: 8.410

10.  Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications.

Authors:  Wenli Feng; Jing Yang; Lu Yang; Qing Li; Xin Zhu; Zhiqin Xi; Zusha Qiao; Wen Cen
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.